0000000000815185

AUTHOR

Giulia Randazzo

showing 2 related works from this author

First detection of SARS-CoV-2 A.23.1 sub-lineage in migrants arriving to Italy via the Mediterranean Sea and public health implications

2021

COVID-19 Mediterranean sea Migrants Molecular surveillance NGS Phylogeny analysis Public health SARS-CoV-2 Vaccination programs2019-20 coronavirus outbreakmedicine.medical_specialtyLineage (genetic)Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Vaccination programsMigrantsArticlePhylogeny analysisMediterranean seamedicineHumansPhylogenyTransients and MigrantsPublic healthSARS-CoV-2Public healthPublic Health Environmental and Occupational HealthCOVID-19VirologyInfectious DiseasesGeographyItalyMolecular surveillanceNGSMediterranean seaTravel Medicine and Infectious Disease
researchProduct

Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI.

2021

Several respiratory pathogens are responsible for influenza-like illness (ILI) and severe respiratory infections (SARI), among which human respiratory syncytial virus (hRSV) represents one of the most common aetiologies. We analysed the hRSV prevalence among subjects with ILI or SARI during the five influenza seasons before the emergence of SARS-CoV-2 epidemic in Sicily (Italy). Respiratory specimens from ILI outpatients and SARI inpatients were collected in the framework of the Italian Network for the Influenza Surveillance and molecularly tested for hRSV-A and hRSV-B. Overall, 8.1% of patients resulted positive for hRSV. Prevalence peaked in the age-groups &lt

medicine.medical_specialtyrespiratory syncytial virusImmunologySettore MED/42 - Igiene Generale E ApplicataVirusArticleInternal medicineDrug DiscoveryEpidemiologymedicinerisk factorsPharmacology (medical)In patientRespiratory systemPharmacologyMolecular epidemiologybusiness.industryPublic healthRvirus diseasesmolecular surveillancevaccinationrespiratory tract diseasesVaccinationInfectious Diseasesrisk factorEtiologyMedicinecommunityrespiratory syncytial virubusinesshospitalizationVaccines
researchProduct